OBJECTIVES: This report focused upon the availability of infection-related health services in substance abuse treatment programs with and without addiction services tailored for special populations (women and non-white populations). METHODS: In a cross-sectional, descriptive design, treatment program administrators across the United States within the National Drug Abuse Treatment Clinical Trials Network provided information on program characteristics, the availability of infection-related services (four medical services and three non-medical services for HIV, HCV, and STI), and barriers to providing infection-related services. RESULTS: Of 319 programs, 269 submitted surveys (84% response rate). Of these, 80% provided addiction services for special populations. Programs providing addiction services designed for at least one special population, were more likely to provide infection-related health services, especially HIV-related education (94% versus 85%, p = 0.05) and patient counseling (76% versus 60%, p = 0.03) and were more likely to include outpatient addiction services (86% versus 57%, p<0.001) and outreach and support services (92% versus 70%, p=0.01). Barriers to providing infection-related services included funding (cited by 48.3% to 74.7% of programs), health insurance (cited by 28.9% to 60.8% of programs), and patient acceptance (cited by 23.2% to 54.3% of programs). CONCLUSIONS: Despite many barriers, infection-related healthcare is available in programs with addiction treatment services tailored for special populations, especially for African Americans and Latino Americans. Tailoring substance abuse treatment along with reducing barriers to infection-related care represent public health interventions with potential to reduce the burdens and disparities associated with these infections.
OBJECTIVES: This report focused upon the availability of infection-related health services in substance abuse treatment programs with and without addiction services tailored for special populations (women and non-white populations). METHODS: In a cross-sectional, descriptive design, treatment program administrators across the United States within the National Drug Abuse Treatment Clinical Trials Network provided information on program characteristics, the availability of infection-related services (four medical services and three non-medical services for HIV, HCV, and STI), and barriers to providing infection-related services. RESULTS: Of 319 programs, 269 submitted surveys (84% response rate). Of these, 80% provided addiction services for special populations. Programs providing addiction services designed for at least one special population, were more likely to provide infection-related health services, especially HIV-related education (94% versus 85%, p = 0.05) and patient counseling (76% versus 60%, p = 0.03) and were more likely to include outpatient addiction services (86% versus 57%, p<0.001) and outreach and support services (92% versus 70%, p=0.01). Barriers to providing infection-related services included funding (cited by 48.3% to 74.7% of programs), health insurance (cited by 28.9% to 60.8% of programs), and patient acceptance (cited by 23.2% to 54.3% of programs). CONCLUSIONS: Despite many barriers, infection-related healthcare is available in programs with addiction treatment services tailored for special populations, especially for African Americans and Latino Americans. Tailoring substance abuse treatment along with reducing barriers to infection-related care represent public health interventions with potential to reduce the burdens and disparities associated with these infections.
Authors: Steven Kritz; Lawrence S Brown; R Jeffrey Goldsmith; Edmund J Bini; Jim Robinson; Donald Alderson; Patricia Novo; John Rotrosen Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Sabrina S Plitt; Richard S Garfein; Charlotte A Gaydos; Steffanie A Strathdee; Susan G Sherman; Taha E Taha Journal: Sex Transm Dis Date: 2005-07 Impact factor: 2.830
Authors: Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais Journal: J Subst Abuse Treat Date: 2012-03-08
Authors: Hyman Hops; Timothy J Ozechowski; Holly B Waldron; Betsy Davis; Charles W Turner; Janet L Brody; Manuel Barrera Journal: AIDS Behav Date: 2011-11
Authors: Lawrence S Brown; Steven Kritz; Edmund J Bini; Ben Louie; Jim Robinson; Donald Alderson; John Rotrosen Journal: J Natl Med Assoc Date: 2010-12 Impact factor: 1.798
Authors: E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan Journal: J Addict Med Date: 2012-06 Impact factor: 3.702
Authors: Susan Tross; Aimee N C Campbell; Donald A Calsyn; Lisa R Metsch; James L Sorensen; Steven Shoptaw; Louise Haynes; George E Woody; Robert M Malow; Lawrence S Brown; Daniel J Feaster; Robert E Booth; Raul N Mandler; Carmen Masson; Beverly W Holmes; Grant Colfax; Audrey J Brooks; Denise A Hien; Bruce R Schackman; P Todd Korthuis; Gloria M Miele Journal: Am J Drug Alcohol Abuse Date: 2011-09 Impact factor: 3.829
Authors: Anjana Roy; Ibrahim Abubakar; Ann Chapman; Nick Andrews; Mike Pattinson; Marc Lipman; Laura C Rodrigues; Jose Figueroa; Surinder Tamne; Mike Catchpole Journal: PLoS One Date: 2011-06-17 Impact factor: 3.240